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Summary 
We demonstrated earlier that individuals homozygous for conserved major histocompatibility 
complex (MHC)-extended haplotypes have low natural killer (NK) activity as measured by cytolysis 
of the K562 tumor cell line. In the present  study, we investigated the segregation  and MHC 
linkage of NK activity in families  in which MHC haplotypes of human histocompatibility leukocyte 
antigens (HLA)-A, -C, and -B, complotype, and DR specificities are known. In two informative 
families, low activity was inherited as a recessive trait linked to the MHC. By using individuals 
homozygous for specific fragments of extended haplotypes or for HLA-B alleles, we found that 
the HLA-C and -B and not the complotype or HLA-DR region contains genes controlling NK 
activity. The majority of the unrelated individuals with low NK activity were homozygous or 
doubly heterozygous  for HLA-B7 (Cw7), B8 (CwT), B44 (Cw5), B18, or B57 (Cw6). Thus, 
these alleles form one complementation group designated NKB1. Another less frequent group, 
NKB2, was also identified, and consisted of individuals homozygous for B35 (Cw4). NK activity 
was correlated with the number of circulating NK (CD16 +  CD56 +) ceils. Individuals homozy- 
gous for the NKB complementation groups have fewer circulating NK ceils than individuals 
heterozygous for these alleles and alleles of other complementation groups, possibly explaining 
the low activity of cells in these subjects. These findings suggest that during the maturation 
of NK calls there is NK cellular deletion in donors homozygous for NKB genes resulting in 
low NK cell numbers and activity. 
G 
enetic control of NK cell activity against tumor cells 
in humans is poorly understood. We had shown earlier 
that  NK cell activity in human MHC homozygotes was 
significantly lower than in heterozygotes  (1). This finding 
suggested that the genes controlling NK activity may be lo- 
cated on chromosome 6. However, it is not known whether 
the genes that control the level of NK cell activity in humans 
are MHC linked nor is it known whether low NK activity 
is the result  of a reduction in NK cell number or per cell 
specific activity. It has recently been reported that the genes 
controlling target antigens  recognized by allospecific NK 
clones are linked to the HLA region (2-6). The rdationship 
between the putative MHC genes controlling NK cell level 
and those determining NK cell targets  is not known. 
Based on our finding that call activity in MHC homozy- 
gotes was lower than in heterozygotes, we hypothesized that 
the putative gene(s) controlling NK activity is (are) recessive 
and in the MHC region, and we suggested that different ex- 
tended MHC haplotypes may also carry different specific al- 
leles for NK activity (1). The genetic material between class 
I and class II MHC loci is relatively fixed on these extended 
haplotypes (7) (see Table 1). Some instances of extended haplo- 
types  appear to have undergone historical  recombinations 
resulting in apparent  fragments  of these haplotypes  in the 
population. These fragments have shorter conserved segments 
than complete extended haplotypes but the shared segments 
appear to be identical. By using these fragments it has been 
possible to map chromosomal regions containing specific genes 
(8-11). Because homozygosity mapping provides a way to 
localize a recessive gene (12), we used homozygosity for ei- 
ther telomeric or centromeric fragments of MHC-extended 
haplotypes to localize the gene(s) controlling NK activity. 
We also investigated the segregation  and MHC linkage of 
NK activity in families in which HLA-A, -C, and -B, com- 
plotype, and DR allele haplotypes were known. In addition, 
we investigated if MHC class I genes affect the development 
of NK cells in vivo. We found evidence for polymorphic reces- 
sive genes controlling NK activity and cell number located 
within the HLA-(C)B region telomeric of the complement 
-DR region of the MHC. 
Materials and Methods 
Subjects.  We studied 29 men and 30 women aged 20-55 yr. 
Five families with 27 members were also studied. Four of these 
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gous for HLA-B and had low NK activity. The unrelated individ- 
uals were previously genotyped for HLA and complotypes, had 
at least one extended haplotype or a fragment of an extended haplo- 
type, and were available for study. The list of extended haplotypes 
used in this study is given in Table 1. We have also included NK 
data on 111 individuals  from 33 families for whom complete HLA 
and complotype data were not available. 
Preparation of Lympkocytes and Cell Cultures.  We used freshly 
isolated or cryopreserved PBMC as a source of NK cells. PBMC 
were obtained from heparinized blood by centrifugation over Ficoll- 
Hypaque density gradients. Cells at the interface were collected 
and then washed in RPMI-1640 supplemented with 100 U/ml pen- 
icillin and 100/~g/ml streptomycin and 2 mM t-glutamine. Cells 
were plated at 37~  to remove adherent macrophages.  The nonad- 
herent cells were gently poured off, washed three times with 5 
ml of culture medium, and used as NK cells. To minimize the effect 
ofcryopreservation on NK activity, cryopreserved PBMC were in- 
cubated overnight at 37~  (1,  13). 
HLA  Typing.  Subjects  were typed for HLA-A, -B, -C,  and 
-DR antigens by a microcytotoxicity assay (14) and for MHC- 
encoded complement proteins C4, BF, and C2 (15-17). Haplotypes 
were assigned  based on family studies. 
Iramunofluorescence  Assay.  To analyze NK cell subpopulations, 
we used two-color immunofluorescence. FITC-conjugated mAb 
Leu-llb (18) (anti-CD16; Becton Dickinson & Co., Mountain View, 
CA) and PE-conjugated Leu-19 (19) (anti-CD56; Becton Dickinson 
& Co.) were incubated with 106 cells for 30 min on ice and the 
labeled cells were washed twice. Background fluorescence was de- 
termined by incubating cells with nonreactive FITC-conjugated, 
and PE-conjugated antibodies.  The simultaneous determination of 
green (FITC) and red (PE) fluorescence was obtained from a single 
laser excitation of both FITC and PE chromophores at 488 nm 
by using a FACS  |  (Becton Dickinson & Co.). A total of 10,000 
cells were analyzed in each  sample and results  were displayed as 
Table  1.  List of Extended Haplotypes 
[Cw7,  B7, SC31, DR2] 
[Cw7,  B8, SC01,  DR3] 
[Cwx, B14,  SC2(1,2) DR1] 
[CwS,  B18, FIC30,  DR3] 
[Cwx,  B18, S042,  DR2] 
[Cw4,  B35, FC(3,2)0, DR1] 
[Cwx,  B38, SC21,  DR4] 
[Cw4,  B44,  FC31,  DR7] 
[Cw5,  B44,  SC30, DR4] 
[Cw6,  B57,  SC61,  DR7] 
[Cwx, B60,  SC02, DR6] 
[Cw3,  B62, SC33, DR4] 
[Cwx, B62, SB42,  DR4] 
Provisional extended haplotypes 
Cw4,  B35, SC31,  DR4 
Cw3,  B60, SC31, DR4 
x refers to undetermined generic type. 
an orthogonal plot. Cryopreserved cells from five individuals were 
tested in parallel with fresh cells for NK activity and for the number 
of cells carrying the CD16 and CD56 markers to test the repro- 
ducibility of  and the effect of  cryopreservadon on the determinations. 
Cytotaxicity  Assays.  NK cell activity was determined using K562 
as a target (1). Briefly, target cells were incubated with 0.1 ml of 
Na2SlCrO4 for 1 h at 37~  followed by three washings  at 4~ 
The final suspension  was made in culture medium. The effector 
cells were mixed in triplicate in 96-well V-bottom microtiter plates 
along with a fixed number of labeled target cells. The microtiter 
plates were spun for 3 min at 200 g. The cell mixtures were in- 
cubated for 4 h at 37~  in a 95% air and 5% COs atmosphere, 
The microtiter plates were spun again for I min at 200 g and 120 
/~1 supernatant was collected and counted in a gamma counter. Per- 
cent cytotoxicity (specific release) was calculated using the formula: 
percent specific release =  100 x  [(E-SR)/(T-SR)],  where E  = 
counts per min (cpm) in the experimental group, SR  =  spontane- 
ously released cpm, and T  =  total cpm incorporated. Spontaneous 
release was obtained from target cells incubated with medium alone 
and was usually <10% of the total count. Total incorporation of 
SlCr was determined by incubating cells in the presence of 0.1% 
NP-40. Percent cytotoxicity was determined at E/T ratios of 100, 
50,  25,  12.5,  and 6.25. 
Data Analysis.  Percent specific release at different E/T ratios 
was used to evaluate the cytotoxic activity of NK cells, expressed 
in LU per 106 effector cells. One LU was defined as the number 
of effector cells required to kill 20% of target cells (10,000 cells 
in the assays used)  (20). 
The experiments consisted of 11 sets using frozen cells (36 indi- 
viduals) and 6 sets using fresh cells (23 individuals).  The NK ac- 
tivity of the cryopreserved PBMC from three or four unrelated 
donors used as controls was tested on 11 occasions and fresh cells 
were tested in parallel with cryopreserved cells on 6 occasions. The 
geometric mean NK activities of these controls were comparable: 
29.5  +  3.6 LU for flesh and 31.7  -+  2.8 LU for frozen cells The 
overall geometric mean lytic activity of fresh and cryopreserved con- 
trol groups was used to normalize the NK data obtained in different 
experiments (21). 
Centroid analysis was used to determine the cutoff  value between 
low and high NK reactors (1, 22). X  2 statistics were calculated for 
analysis of 2  x  2 contingency tables prepared from Tables 2 and 
3. Statistical analysis was performed using Student's t test for com- 
parison of different groups (23). Family data were analyzed using 
a method proposed by Smith (24). 
Results 
The analysis of NK  activity in  59 unrelated  individuals 
showed two groups. In one group, 21 subjects, including three 
individuals from four of the five families, had low activity 
(~7 Lid). There was no significant difference in NK activity 
due to gender. 
Putative NK Genes Map to the HLA-C/B Region.  Table 
2 shows 12 individuals with low NK activity who had ex- 
tended haplotypes or fragments of them. Five of them were 
homozygous for HLA-B(C) complotype whereas five were 
homozygous for HLA-B(C) only. Table 2 also shows 10 in- 
dividuals who were not homozygous for HLA-B but were 
homozygous for complotype, DR, or both, 9 of whom were 
high NK reactors. The frequency of low reactor individuals 
homozygous for HLA-B only, or homozygous for HLA-B 
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Code  Haplotypes  LU  Code  Haplotypes  LU 
Homozygotes 
BII-I* 
GT-I 
A-2 
BTII- 1 * 
SBI-2*  A2,  DR1  1 
A24,  DR4 
D- 1  [A3,  DR2]  3 
A2,  DR4 
E-6  [A3,  DR2]  3 
A2,  DR4 
J-4*  DRx  7 
DR2 
H-5  DR4  1 
DRI 
Q-8  DR4]  5 
DR2 
V-9  DR4]  3 
DR7] 
KL-3  DR7]  4 
DR4 
K-10  DR6]  3 
DR4 
Heterozygotes 
N-15  [11,  Cw7,  BS, 
A33,  Cw3,  B57, 
SBII-2*  124, i::  ;~!::  B35, 
[12,  ;~: }:C4wxi  B44, 
￿9 .  ::::::::  ￿9 
::::::::::::::::::::: 
Br-2  A2g,  B41, 
A2,  :i~:i~i!i i  B49, 
:5:: ::::::2:::::::  ; 
0-5*  [13, i  !eN~  i  B7, 
A2,  B51, 
:'::5:':::::.  ::.::::5::" 
:  :::::2::::.: 
P-16*  A2,  ; :iiC~::  B 18, 
:.::::5:::  ::::2 
:"'"  :::  :5:::::::'"5 
Fa-M  [128,i:  ~:;  B44, 
13,  i:)::!~}:  I  BI4, 
:  +. 
F1- 2  B 44, 
B27, 
Fa-Fo  B51, 
B60, 
Sr-2  B51, 
B58, 
iiiii~iiii~i~iiiiiiiiiiiiii~iii 
4 
90 
79 
DR7  15 
DR4 
DR2]  14 
DR6 
18 
59 
89 
99 
19 
* Also listed  in Figs.  1A,  1C,  1D,  and Tables  3  and 4. 
Shaded areas represent homozygous regions of HLA haplotypes. Lightly shaded areas represent HLA-C locus with incomplete typing information. 
Bracketed alleles denote conserved extended haplotypes, and fragments of conserved haplotypes are underlined. 
and complotype, was significantly higher than that for those 
homozygous for DR and complotype (P <0.005 in each case). 
Low NK Activity Is a Recessive Trait.  Our initial study con- 
sisted of the analysis  of NK cdl activity of 136 individuals 
bdonging to 37 families with two parents and at least one 
child.  There were nine families in which at least one child 
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was a low reactor.  In five of the nine families,  one parent 
had low NK activity and in rest of the four families,  both 
parents had high NK activity. The observed number of low 
reactors,  10, in this sample was not significantly different from 
that expected on the basis of mendelian segregation (X  2 -- 
0.49, P >0.1). This suggests that the gene(s) responsible for low activity is (are) recessively  inherited. All 13 homozygotes 
(12 for extended haplotypes  or HLA-B regions and one for 
HLA-B51)  had low NK activity.  11 out of 43 individuals 
heterozygous  for HLA-B (Cw) alleles had low NK activity. 
Again, these data are consistent with recessive genes control- 
ling low NK activity and suggest that homozygosity for an 
MHC gene  is necessary to confer low NK activity. 
Polymorivhism of NK Activity.  Based on our NK data, we 
categorized individuals in four groups based primarily upon 
homozygosity or heterozygosity for specific haplotypes  or 
fragments thereof(Tables  3, 4, and 5). Table 3 shows the NK 
activity of individuals heterozygous for extended haplotypes 
[HLA-Cw7, B8, SC01, DR3], [HLA-Cw7, B7, SC31, DR2], 
[HLA-Cw5, B44, SC30, DR4] or their fragments. The first 
group contains  the majority of the low NK reactors in the 
MHC heterozygous group with two haplotypes or fragments 
of them containing  HLA-B7 (Cw7), B8 (Cw7), B18, B44 
(Cw5), or B57 (Cw6). These B(C) alleles were assigned to 
Table 3.  NK Activity of Heterozygous Subjects Sharing Alleles of Two Extended Haplotypes (NKB1 Homozygous), or Fragments of 
Extended Haplotypes Marked by HLA-B Alleles: B7, B8, B18, B44, and B57 
Code  Haplotypes  LU  Code  Haplotypes  LU 
Group A (HLA-B heterozygous : NKB1 homozygous)  Group B (HLA-B heterozygous : NKB1 heterozygous) 
He-2  [A1, Cw7,  B8, SC01, DIL3]  3  FN-5 
[A3, Cw7, B7, SC31, DR2] 
P-1  [A1, Cw7, BS, SC01, DR3]  4  Fa-M 
[A3, Cwy, B7, SC31, DR2] 
BI-I*  [A1, Cw7,  BS, SC01, DK3]  6  Mo-P 
[A2, CwS, B44, SC30, DR4] 
BI-2*  [A1, Cw7, B8, SC31, DR3]  5  LuK 
[A23, Cw4,  B44, FC31, DR7] 
BII-2*  [A1, Cw7, BS, SC01, DR3]  2  Ryg 
[A2, CwS, B44, SC30, DR4] 
M-11  [A1, Cw7, B8, SC01, DR3]  4  DJ 
A1, Cwx, B18, SC01, DR3 
Wa-3  [A3, Cwx, B7, SC31, DR2]  5  AN 
A2, Cwx, B57, FC30, DR4 
D-Bo  A2, Cwx, B7, SC31, DR1  1  CA 
A25, Cwx, B18, SC02, DR5 
Sd-4  A3, Cwx, B44, SC31, DR3  1  Fi-5 
A2, Cwx, B57, SC60, DR4 
Ma-Ko  [A23, Cwx, B7, SC31, DR2]  23  F1-2 
Ax, Cwx, B18, SC02, DR5 
M-15  [A1, Cw7,  BS, SC01, DR3]  90  A-31" 
A33, Cw3, B57, SC01, DR3 
P-16  A2, Cwx, B18, SC02, DR5  18  O-5" 
A3, Cwx, B57, SC61, DR5 
Ug-4  [A1, Cw7, BS, SC01, DR3]  20  Bu-1 
A26, Cwx, B44, SC31, DR5 
P-4  [A1, Cwx, BS, SC01, DR3]  78 
A2, Cwx, B7, SC31, DR4 
A2, Cwx, B7, SC31, DR9  47 
All,  Cw4, B53, SC31, DR1 
[A28, Cwx, B44, SC30, DR4]  59 
A3, Cwx, B14, FC31, DR4 
A2, Cw5, B44, SC31, DR2  63 
A2, Cw3, B62, SB42, DRx 
A3, Cwx, B18, SC01, DR5  46 
A3, Cwx, B49, SC31, DR4 
A3, Cwx, B18, SC01, DR5  89 
A1, Cwx, B13, SC33, DR7 
A1, Cwx, B18, SC31, DR5  78 
A3, Cwx, B39, SC30, DR2 
A24, Cwx, B18, SC01, DR1  83 
A2, Cwx, B50, $1C21, DR7 
A2, Cwx, B18, SC31, DR5  33 
A1, Cwx, B14, SC02, DRx 
A2, Cw2, B44, SC31, DR1  69 
A2, Cwx, B37, FC30, DR2 
A2, Cwx, B44, SC31, DR2  89 
A2, Cw2, B27, SC42, DR2 
[A2, Cwx,  B8, SC01, DR3]  17 
A2, Cw3, B62, SC33, DR1 
[A3, Cw7, B7, SC31, DR2]  14 
A2, Cwx, B51, SC31, DR6 
A26, Cwl, B51, SC31, DR6  58 
A33, Cw3, B57, SC30, DR3 
* Also listed in Table 4 and Fig. 1 D. 
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group of  low responders (group A) and high responders (group 
B). Group A individuals were doubly heterozygous for HLA- 
B(C) alleles of NKB1, whereas group B individuals were het- 
erozygous for one NKB1 and one non-NKB1 allele. Individ- 
uals  heterozygous for  HLA-B18  (Cw3)  and  HLA-B57 
(Cw6) were also included in this group even though the status 
of these alleles is less clear. 9 of the 14 individuals denoted 
as homozygous for NKB1 had low NK activity (group A, 
Table 3). The degree of association between homozygosity  at 
NKB1 and low NK activity is 0.68 (X  2 =  12.5, P <0.001). 
The second group is made up of two individuals homozy- 
gous for HLA-B35 (Cw4) and one heterozygous  for HLA-B62 
(Cw3)/HLA-B35 (Cw4), all of whom showed low activity. 
These aUdes  were phced in group A of  the NKB2 complemen- 
tation group.  In eleven individuals who were heterozygous 
for these haplotypes and haplotypes with non-NKB1  alldes 
who had high NK activity, the non-NKB1/MHC alleles  were 
placed in the group NKB2 (Table 4). Confirmation of this 
group came from the results of family BT (Fig. 1 C). Three 
members of this  family exhibiting low NK activity were 
homozygous for HLA-B35 (Cw4), and 9 of 12 independent 
examples of heterozygous B35 (Cw4) donors had high NK 
activity and were presumably heterozygous for the putative 
NKB1  and NKB2  complementation groups.  Because one 
HLA-B35/B62 individual,  NK activity was low (Table 4), 
and two individuals with B62 together with a haplotype as- 
sociated with the first complementation group (B8 or B44) 
had high NK activity, this haplotype was tentatively assigned 
to the complementation group NKB2 even though one HLA- 
B15 (?62)/B35  subjects had high activity. Table 5 shows in- 
dividuals who did not have HLA-B alleles of the two defined 
complementation groups. 9 of 10 had high NK activity. The 
one individual  exhibiting low NK activity carried  HLA- 
B14/B38 haplotypes. HLA-B14-carrying individuals could 
not be part of the NKB1 complementation group because 
Table 4.  NK Activity of Donors with Extended  Haplotypes or Fragments Associated with B35 Alleles 
Code  Haplotypes  LU  Code  Haplotypes  LU 
Group A (NKB2 homozygous) 
J-4  A3, Cw4, B35, SC31, DRx  7 
A3, Cw4, B35, FC31, DR2 
SBI-2*  A2, Cw4, B35, SC30, DR1  1 
A24, Cw4, B35, SC30 DR4 
Group B (HLA-B heterozygous: NKB1/NKB2) 
Q-7  A28, Cw4, B35, SC31, DR5  25 
[A1, Cw7, B8, SC01, DR3] 
T-8  A28, Cw4, B35, SC31, DR8  35 
[A1, Cwx, BS, SC01, DR3] 
L-Co  All, Cwl, B35~ SC31, DR5  80 
[A30, Cwx, B18, F1C30, DtL3] 
Fa-R  A32, Cw4, B35, SC31, DR5  56 
A24, Cwx, B18, FC31, DR2 
BA-4  A1, Cw4, B35, SC31, DR5  61 
[A23, Cw4, B44, FC31, DR7] 
SBII-2*  A24, Cw4, B35, SC30, DR4  79 
[A2, Cwx, B44, SC30, DR4] 
Mo-F  A24, Cwx, B35, SC31, DR4  14 
A2, CwS, B44, SC30, DR2 
Ja-R  A32, Cw4, B35, SC31, DR5  21 
A24, Cwx, B18, FC31, DR2 
Group C (H-LA-B heterozygous: NKB2/NKBX) 
AW  A3, Cw4, B35, FC30, DR1  22 
A24, Cwx, B39, SC42, DR8 
Tr-5  A28, Cw4, B35, SC31, DR8  13 
A3, Cwx, B51, FC30, DK6 
Bat-2  A1, Cw4, B35, SC01, DR5  43 
A24, Cw3, B15, FC31, DR4 
Y-1  [A2, Cw4, B35, SC31, DR4]  4 
A2, Cw3, B62, SC32, DR1 
* Also listed in Fig. 1 A. 
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Complementation Groups 
Code  Haplotypes  LU 
FM-1  A25, Cw2, B51, FC30, DR5  53 
[All, Cw4, B60, SC31, DR4] 
Fa-Fo  A2, Cwx, B51, FC30, DR6  99 
[A2, Cw3, B60, SC02, DR6] 
E-Fo  A2, Cwx, B51, FC30, DR6  24 
A3, Cwl, B27, SC31, DR4 
St-Tr  A2, Cwl, B27, SC42, DR7  35 
A28, Cwx, B37, FC30, DR4 
Bi-3  A2, Cw4, B38, SC31, DR6  21 
A29, Cwl, B53, SC30, DR7 
Br-2  A28, Cwx, B41, SC31, DR7  15 
A2, Cwx, B49, SC31, DR4 
KS  A2, Cwx, B14, SC02, DR1  34 
A1, Cwx, B58, SC21, DR4 
IM  All, CW1,  B27, SC32, DR1  95 
A33, Cwx, B14, SC42, DIL8 
Nu-3  A29, Cwx, B14, FC31, DR1  1 
A3, Cwx, B38, SC30, DR6 
Sr-2  A2, Cwl, B51, SC31, DtL5  19 
A2, Cwl, B58, FC31, DR5 
Mo-R  A24, Cw3, B62, FC31, DR2  40 
A25, Cwx, B39, SC31, DtL5 
we found two cases (B14/B18 and B14/B44) with high NK 
activity (see Table 3, group B). With the information avail- 
able, these individuals could not be assigned to any of the 
two complementation groups and the alleles were therefore 
assigned to NKBx. 
Family Studies of Individuals with Low NK Activity.  Four 
of five families studied were informative for inheritance and 
segregation of  low NK activity with the MHC and are shown 
in Fig. 1. In the fifth family, the parents and two children 
had high NK activity and none of the members were homozy- 
gnus for HLA or for the three putative NKB complementa- 
tion groups (data not shown). In Fig.  1 A, a low reactor, 
SBI-2, was homozygous for NKB2 (Cw4, B35, SC30). The 
siblings, SBII-1 and SBII-2, carried the NKB2 (HLA-Cw4, 
B35, SC30, DR3) haplotype from the mother (SBI-2) and 
the extended haplotype NKB1 [HLA-Cwx, B44, SC30, DR4] 
from the father (SBI-1). As expected on the basis of recessive 
inheritance,  the two children heterozygous for NKB, each 
inheriting NKB1 and NKB2 haplotypes from their parents, 
showed high NK activity. In Fig. 1 B, the mating between 
parents heterozygous for NKB resulted in three out of the 
four children being homozygous for the NKB2 haplotype. 
Two out of these three children were low reactors. The third 
sibling homozygous at NKB (CII-4) had high NK activity 
which could be due to either recombination between HLA- 
(C)B and the putative NKB allele or due to a gene outside 
the MHC influencing NK activity. Further proof of the segre- 
gation of low NK activity with homozygosity  at HLA-(C)B 
or NKBx was obtained in Fig. 1 C in which all three siblings 
who were homozygous for HLA-B51, SC31, DR6 also had 
low activity. The gene(s) controlling low activity is (are) in 
a region dose to HLA-(C)B on chromosome 6. Fig. 1 D gives 
an interesting example of a family in which homozygosity 
at NKB and not HLA-(C)B leads to low NK activity. The 
two parents, BI-1 and BI-2, are homozygous for the putative 
NKB1 haplotype but are heterozygous at the HLA-B locus. 
As expected, all siblings who were homozygous for the NKB1 
haplotype but who were heterozygous  for I-ILA-(C)B alleles 
showed low NK activity. These examples thus provide fur- 
ther evidence that (a) low NK activity segregates  with homo- 
zygosity for NKB alleles and (b) the gene(s) controlling low 
NK is (are) located in the MHC. 
SugCace Marker Analysis of NK Cells.  Because  the majority 
(>90%) of NK activity resides in the CD16+CD56 + cell 
population  (19), we used two-color immunofluorescence to 
define the NK cell population in PBMC from 41 individuals 
using mAbs specific for those determinants.  The frequency 
of the CD16+CD56 + cells in our population ranged be- 
tween 3.8 and 20.5% of mononuclear cells. Examples of two 
individuals, one with a low number of CD16 +  CD56 + cells 
(9.5%) and homozygous for NKB1,  and the other with a 
high number of CD16+CD56 + cells (19.1%) and heterozy- 
gnus for NKB1,  are shown in Fig. 2.  The mean value of 
CD16+CD56 + of NKB1  homozygotes was 8.8  _+  3.2% 
(n  =  8)  and for NKB2  homozygotes was  7.9  _+  3.0% 
(n =  6). Fig. 3 shows that individuals  heterozygous for NKB1, 
NKB2, and NKBx groups have a higher cell number, 14.4 _+ 
0.7% (n =  27), than individuals homozygous for NKB1 or 
NKB2 (Student's  t test,  both P <0.01). 
Discussion 
Our studies were undertaken to investigate the relation- 
ship between antitumor NK activity and homozygosity for 
extended haplotypes or fragments of them to (a) determine 
whether or not genes in the MHC control NK cell activity; 
(b) to localize the region containing the NK effector gene(s); 
and (c) to determine whether low NK activity was the result 
of low NK cell number. We have confirmed the relationship 
between homozygosity  for extended haplotypes and low NK 
activity and extended our findings to show that fragments 
heterozygous  for some specific  extended haplotypes may also 
carry the low NK phenotype. Although our family studies 
are preliminary, the results suggest that recessive  gene(s) con- 
trolling NK activity are localized in a region close to HLA- 
(C)B and they may act by specifying low NK cell number 
or/and activity. We found that high responders are primarily 
in the MHC heterozygous group. The low responders were 
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Figure  1.  (A-D)  Family trees.  HLA markers on each haplotype are listed below the tree.  Extended haplotypes are shown in brackets.  Fragments 
of extended haplotypes are underlined. Cytotoxic activity is given in terms of LU as defined  in the text. 
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Figure 2.  Two-color  immunofluorescence  analysis of PBMC. Cells  were 
analyzed for simultaneous expression of CD16 and CD56 antigens by a 
direct immunofluorescence  method. Directly conjugated mAbs anti-Leu 
11b-FITC and anti-Leu 19-PE  were  used  in this assay. Background  fluores- 
cence was determined by incubating cells with  a nonreactive FITC- 
conjugated antibody and a nonreactive PE-conjugated antibody. The 
x-axis is green fluorescence  and the y-axis is red fluorescence. 10,000 cells 
per sample were analyzed. The four quadrants (Qa) represent Qa-1, 
CD16-CD56+; Qa-2, CDI6+CD56+; Qa-3, CD16-CD56-; and Qa-4, 
CD16+CD56 - . Actual values as percentage of total PBMC with CD16 
and CD56 are (A) Qa-l: 1.6, Qa-2: 19.1, and Qa-4: 4.6; (B) Qa-l: 4.7, 
Qa-2: 9.5, and Qa-4: 4.3. 
found with higher frequency among HLA-(C)B homozygotes. 
Based on NK activity of unrelated individuals, at least three 
complementation groups: NKB1, NKB2, and NKBx were 
defined. From the frequencies of HLA-B fragments of different 
extended haplotypes, we estimate that  no more than  30% 
of individuals  in the Caucasian population have low antitumor 
NK activity. 
20 
15 
b 
Figure 3.  Phenotypic  analysis 
of  NK  cell subset (CD16  + 
CD56 +) in PBMC of individuals 
homozygous  for the putative NK 
genes, NKB1 and NKB2, and het- 
erozygous for these alleles. The 
results are presented as the mean 
percentage of positive  cells _+ SD 
for each group as identified by 
simultaneous  two-color  im- 
munofluorescence analysis  of 
10,000 cells. The mean values of 
CD16+CD56 +  cells  as  per- 
centage of PBMC for homozy- 
gores and heterozygotes  for NKB1 
and NKB2 are 8.8  _+ 3.2 (n  = 
NKB1  NK~.  NK1B  8), 7.9 + 3.0 (n  =  6), and 14.4 +- 
i  t  i  i 
.o~*.  .=e,o~got*=  3.5 (n  =  27), respectively. 
Much of the information on the genetics of NK activity 
against tumor cells comes from studies in the murine system 
(25-28). The NK cell population is heterogeneous (29, 30); 
high NK activity is inherited in a dominant fashion and is 
linked to the H-2D end of the MHC region (27, 28). NK 
cells are the effectors of hybrid resistance (26, 31).  Hybrid 
resistance in mice is under the control of Hh genes which 
are inherited recessively (32-34). NK cells also recognize an 
antigen present on hematopoietic cells (32, 34). Although 
the nature of this target antigen is still unknown, it has been 
suggested that  the Hh genes control the expression of the 
target antigens (35). Specific NK cell subsets recognize allele- 
specific Hh-1 antigens on hematopoietic cells (36, 37). These 
antigens may be responsible for the genetic specificity ob- 
served in hybrid resistance.  The Hh genes are located close 
to the H-2D and S regions of MHC and are polymorphic 
(28,  33-35).  These  genes  appear  to  be distinct  from  the 
H-2D/L alleles (38), although evidence from studies of trans- 
genic mice suggests that  the gene controlling hybrid resis- 
tance in  some strains  may itself be the H-2D allele  (39). 
The existence of hybrid resistance in humans is not known. 
AUogeneic reaction to hematopoietic cells by NK clones has 
been used as an in vitro model to study the genetic control 
of NK cell-hematopoietic cell interactions (2). These studies 
revealed that the "susceptibility to lysis" phenotype of PHA 
blasts of normal cells is inherited recessively and the suscep- 
tibility or resistance  to lysis phenotype segregated with HLA 
haplotypes (2, 3). Based on our observation that low activity 
is associated with homozygosity at the HLA, -(C)B loci, sug- 
gesting recessive inheritance, we hypothesize that, as in mice, 
individuals  homozygous for NKB alleles will express NK 
target determinants and will be sensitive to lysis by NK clones, 
and that individuals heterozygous for different NKB alleles 
will lack expression of NK target  determinants  and hence 
will be resistant to lysis by NK cells.  When we reanalyzed 
the HLA data of the family reported earlier by Ciccone et 
al.  (2), we observed that  the T  cells from 16 our of the 17 
individuals resistant to lysis by NK clones were heterozygous 
for the NKB1, NKB2, or NKBx complementation groups. 
This is in keeping with the hypothesis that heterozygosity 
for these complementation groups that produce high NK ac- 
tivity also determine or mark resistance to lysis.  The data 
reported by Ciccone et al. (2) also show that homozygosity 
for HLA-B and not DR alleles leads to the expression of NK 
target antigens,  again suggesting that the NK target-deter- 
mining genes map to the same HLA-(C)B region as NK cell 
number-determining genes. Our estimate of the upper limit 
of the frequency of individuals with low NK activity is close 
to that of the frequency of individuals carrying the pheno- 
type for susceptibility to lysis as reported by Ciccone et al. 
(2).  Furthermore,  it has been shown that  a subset of NK 
cells recognize target cells homozygous for HLA-B7, B8, B18, 
B44, B57, and B60 alleles corresponding to the NKB1 com- 
plementation group (40). Thus, the pattern of resistance or 
susceptibility to lysis phenotypes in these studies fits the predic- 
tions of our genetic model of NK polymorphism,  and pro- 
vides independent evidence for the existence of NKB com- 
plementation groups determining NK cell number and activity 
1200  Genetics  of Human Natural Killer Cells as shown by the present studies. Whether or not these genes 
for different activities not only colocalize but are the same 
remains to be shown. 
Another important finding in our current study is that 
individuals homozygous for NKB complementation groups 
have a lower NK ceil number which may account for low 
activity. In a study using mice homozygous for a mutant 
~2-microglobulin allele,  it was observed that  there was  a 
significantly reduced cytotoxic activity of splenic NK cells 
against tumor cells as well as class I-deficient T  cell blasts 
(41). The mechanism responsible for this reduced activity of 
NK cells is not known. The low activity and reduced fre- 
quency of NK cells in homozygous individuals in our study 
could be due to either partial deletion or a defect in differentia- 
tion, or both, during development of NK (CD16 +  CD56 +) 
cells in vivo. In NKB homozygous individuals, the develop- 
ment of the class I-related component of NK activity may 
be defective, resulting in the lower frequency of NK cells or 
to a decrease in lytic activity per cell. Since the killing of 
target cells involves recognition of and binding to the target 
antigens and subsequent release oflytic molecules by effector 
cells, the signal for the release oflytic molecules may be under 
the control of class I-linked Hh genes. Better understanding 
of structure and function of NK receptors and associated mol- 
ecules involved in signal transduction will help in under- 
standing the mechanisms of class I-related regulation of NK 
activity. Because recognition of self-MHC class I alleles pro- 
vides a negative signal to NK cells, it has been suggested that 
a positive signal selection step during NK ceil development 
may be responsible for defining self-MHC class I (41). Re- 
cent studies showed that the expression of the Ly-49 antigen, 
a molecule expressed on a subset of NK cells in mice (42), was 
strongly downregnlated in B10  (H-2  b) NK cells  obtained 
from mixed allogeneic chimeras, suggesting that differentia- 
tion of NK cells is indeed determined by the MHC  (43). 
To explain the recessive inheritance of Hh antigen expres- 
sion, the existence of codominant transacting regulatory genes 
has been proposed (34,  35, 44). According to this hypoth- 
esis, the expression of the Hh-1 hybrid resistance target pbeno- 
type is governed by the presence or absence of the down- 
regulatory genes. One possible candidate molecule as a target 
subjected to downregulatory gene action could be MHC dass 
I antigens. Tumor cells or class 1-deficient cells are highly 
susceptible to NK-induced lysis (41, 45-48). When these class 
I-deficient cells were transfected with class I genes, the trans- 
fectants became resistant to lysis, suggesting that the expres- 
sion of class I antigens on target cells causes resistance to lysis. 
Using site-directed mutagenesis, it was shown that the pres- 
ence of the residue Asp at position 74 within the peptide- 
binding groove of a class I molecule renders the target cells 
resistant to lysis by NK ceils (47). Also, it was reported that, 
in  mice,  Ly-49 +  cells  bind  the MHC  class  I  alloantigen 
H-2D  a but not other class I antigens and protect from lysis 
(49). More recently, it was reported that the presence of amino 
acids at positions 77 (Set) and 80 (Asn) of HLA-Cw3 confers 
resistance to lysis by some alloreactive NK clones which be- 
long to a subpopulation of NK cells (50). This suggests that 
NK cells possess receptors which specifically recognize and 
bind peptides that are part of the class I molecules and pro- 
tect the target cells from lysis. To explain the protection of 
target cells from NK-induced lysis, it has been suggested that 
the binding of some NK cells to a class I-associated target 
structure induces a negative signal which protects cells from 
NK-induced lysis. This hypothesis may apply to at least some 
human NK calls, as it was observed that a mAb, anti-p58, 
which recognizes a subset of NK cells which specifically binds 
a determinant present on HLA-C antigen or associated with 
it, can block or abrogate the resistance to NK cell-induced 
lysis of the appropriate target cells (51, 52).  Further studies 
demonstrated that the presence of HLA-B and HLA-C al- 
Ides confer more protection than HLA-A molecules (53). 
It is likely that some, but not all, alleles of the class I loci 
may act in the protection of targets from NK cell-induced lysis. 
We suggest that the information in this paper will enable 
us to further investigate the genetics of NK cell activity in 
humans. This, it is hoped, will lead to an understanding of 
Hh genetics in humans. Such findings could be of impor- 
tance in bone marrow transplantation. 
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